NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the Un
Related Questions
What is the company’s current debt level and liquidity position after the quarter’s results?
Is there any information on upcoming product launches, regulatory approvals, or pipeline developments that could impact future revenue?
How much of the revenue growth is attributable to the $10.3 million Motiva sales versus other product lines?
What was the net income and earnings per share for Q2 2025, and how does it compare to the prior year?
Did the company provide any updated guidance or outlook for Q3 2025 and the full‑year 2025?
What is the gross margin on the $51.3 million revenue and has it improved versus the previous quarter?
How does ESTA’s Q2 2025 performance compare to its main competitors in the breast‑aesthetics and reconstruction market?
How might the 16.3% YoY revenue growth influence analyst sentiment and the stock’s price trajectory in the near term?
Are there any notable changes in the geographic mix of sales (e.g., U.S. vs international) that could affect future growth?
What are the cash flow and capital expenditure expectations given the recent revenue increase?